174 related articles for article (PubMed ID: 35594654)
1. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
[TBL] [Abstract][Full Text] [Related]
2. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
4. Discovery of highly potent and selective CRBN-recruiting EGFR
Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of selective degraders of EGFR
Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
[TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract][Full Text] [Related]
11. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
[TBL] [Abstract][Full Text] [Related]
16. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFR
Tian L; Li X; Lv Z; Yang Y; Wang L; Xu D; Ma X; Xu Y
Bioorg Med Chem; 2022 Nov; 74():117052. PubMed ID: 36288657
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
Wu H; Wang A; Zhang W; Wang B; Chen C; Wang W; Hu C; Ye Z; Zhao Z; Wang L; Li X; Yu K; Liu J; Wu J; Yan XE; Zhao P; Wang J; Wang C; Weisberg EL; Gray NS; Yun CH; Liu J; Chen L; Liu Q
Oncotarget; 2015 Oct; 6(31):31313-22. PubMed ID: 26375053
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR
Fu J; Yu J; Zhang X; Chang Y; Fan H; Dong M; Li M; Liu Y; Hu J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205605. PubMed ID: 37106478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
